Osteoporosis Postmenopausal

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA withdrawal · 2018-12-12
EMA Withdrawn: Zoledronic acid Teva Pharma (zoledronic acid) — Teva B.V.
EMA withdrew zoledronic acid Teva Pharma (zoledronic acid) from the market in 2018 for indications including osteoporosis, osteitis deforman…